Skip to main content
. 2022 Mar 30;29(6):474–486. doi: 10.1111/jvh.13672

TABLE 2.

Characteristics of patients with detectable viraemia 12 weeks post‐treatment overall and from each observational cohort or Clinical Trial Registry

Total cohort Clinical Trial Registry 1 e Clinical Trial Registry 2 e US Veterans Affairs b Egypt a UK b Georgia a Myanmar d
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Baseline VL (IU/ml), millions 2.6 6.1 9.6 8.2 5.5 5.9 4.3 5.8 2.1 6.5 1.7 3.5 1.9 4.7 4.9 7.7
VL at 12‐week SVR (IU/ml), millions f 1.8 5.5 6.5 7.5 4.2 6.4 2.7 6.2 1.6 5.9 1.1 2.5 0.9 2.6 1.7 2.8
VL at 12‐week SVR log (IU/ml) 5.1 1.4 6.4 0.7 6.0 1.3 5.7 1.1 5.0 1.4 4.9 1.5 4.6 1.5 4.8 1.7
Treatment duration, days 107 41 NA 99 44 98 29 106 37 86 17 126 56 84 0
n % Only RNA data n % n % n % n % n % N %
Sample of post‐treatment viraemic patients 5,973 100% 68 100% 173 100% 1125 100% 3264 100% 131 100% 1041 100% 84 100%
Demographic characteristics
Sex
Male 4,344 73% 158 91% 1106 98% 1943 60% 113 86% 892 86% 82 98%
Female 1,561 26% 15 9% 19 2% 1321 40% 18 14% 149 14% 2 2%
Age (years)
<60 3,880 65% 126 73% 252 22% 2388 73% 101 77% 859 83% 81 96%
>60+ 2,009 34% 31 18% 873 78% 876 27% 30 23% 182 17% 3 4%
Missing 16 0% 16 9% 0 0% 0 0% 0 0% 0 0% 0 0%
HIV antibody coinfection 154 3% 13 8% 38 3% 0 0% 7 5% 0 0% 75 89%
HBsAg‐positive 119 2% 0 0% 76 7% 9 0% 1 1% 25 2% 5 6%
Disease characteristics
Fibrosis FIB4
F0–F1 (FIB4 < 1.45) 1,539 26% 27 16% 193 17% 991 30% 2 2% 252 24% 54 64%
F2–F3 (3.25 ≥ FIB4 ≥ 1.45) 1,764 30% 50 29% 403 36% 967 30% 15 11% 294 28% 21 25%
F4 (FIB4 > 3.25) 2,473 41% 60 35% 529 47% 1294 40% 74 56% 486 47% 9 11%
Missing 129 2% 36 21% 0 0% 12 0% 40 31% 9 1% 0 0%
Genotype g
1a 733 12% 49 28% 659 59% 0 0% 25 19% 0 0% 0 0%
1b 177 3% 16 9% 156 14% 0 0% 5 4% 0 0% 0 0%
1 (unknown subtype) 478 8% 0 0% 44 4% 109 3% 8 6% 294 28% 2 2%
2 315 5% 16 9% 81 7% 0 0% 4 3% 212 20% 0 0%
3 734 12% 89 51% 160 14% 23 1% 83 63% 324 31% 36 43%
4 3,154 53% 2 1% 17 2% 3132 96% 3 2% 0 0% 0 0%
5 2 0% 1 1% 1 0% 0 0% 0 0% 0 0% 0 0%
6 30 1% 0 0% 1 0% 0 0% 0 0% 0 0% 0 0%
Mixed genotype 37 1% 0 0% 6 1% 0 0% 3 2% 0 0% 28 33%
Unknown 227 4% 0 0% 0 0% 0 0% 0 0% 211 20% 0 0%
Treatment characteristics
Treatment duration
6/8 weeks h 46 1% 41 24% 0 0% 0 0% 5 4% 0 0% 0 0%
12 weeks 4,197 70% 77 45% 886 79% 2406 74% 106 81% 563 54% 84 100%
16 or 20 weeks 187 3% 17 10% 97 9% 0 0% 1 1% 72 7% 0 0%
24 weeks 1,423 24% 37 21% 142 13% 858 26% 4 3% 370 36% 0 0%
48 weeks 37 1% 1 1% 0 0% 0 0% 0 0% 36 3% 0 0%
Missing 15 0% 0 0% 0 0% 0 0% 15 11% 0 0% 0 0%
DAA era i
Early 1,613 27% 83 48% 146 13% 878 27% 3 2% 488 47% 0 0%
Mid 3,918 66% 22 13% 798 71% 2386 73% 123 94% 517 50% 0 0%
Recent 374 6% 68 39% 181 16% 0 0% 5 4% 36 3% 84 100%
Ukraine e Cambodia c Mozambique c Pakistan c
Mean SD Mean SD Mean SD Mean SD
Baseline VL (IU/ml), millions 3.3 4.2 3.5 5.3 0.7 1.0 0.3 0.2
VL at 12‐week SVR (IU/ml), millions f 2.0 3.2 2.7 4.7 0.3 0.5 0.5 0.7
VL at 12‐week SVR log (IU/ml) 4.7 1.9 5.4 1.5 3.9 2.3 4.9 1.3
Treatment duration, days 84 0 84 0 84 0 121 43
n % n % n % n %
Sample of post‐treatment viraemic patients 17 100% 40 100% 3 100% 27 100%
Demographic characteristics
Sex
Male 11 65% 26 65% 3 100% 10 37%
Female 6 35% 14 35% 0 0% 17 63%
Age (years)
<60 17 100% 28 70% 3 100% 25 93%
60+ 0 0% 12 30% 0 0% 2 7%
Missing 0 0% 0 0% 0 0% 0 0%
HIV antibody coinfection 13 76% 5 13% 3 100% 0 0%
HBsAg‐positive 2 12% 1 3% 0 0% 0 0%
Disease characteristics
Fibrosis FIB4
F0–F1 (FIB4 < 1.45) 13 76% 4 10% 3 100% 0 0%
F2–F3 (3.25 ≥ FIB4 ≥ 1.45) 3 18% 10 25% 0 0% 1 4%
F4 (FIB4 > 3.25) 1 6% 19 48% 0 0% 1 4%
Missing 0 0% 7 18% 0 0% 25 93%
Genotype g
1a 0 0% 0 0% 0 0% 0 0%
1b 0 0% 0 0% 0 0% 0 0%
1 (unknown subtype) 10 59% 10 25% 1 33% 0 0%
2 0 0% 1 3% 0 0% 1 4%
3 7 41% 0 0% 0 0% 12 44%
4 0 0% 0 0% 0 0% 0 0%
5 0 0% 0 0% 0 0% 0 0%
6 0 0% 29 73% 0 0% 0 0%
Mixed genotype 0 0% 0 0% 0 0% 0 0%
Unknown 0 0% 0 0% 2 67% 14 52%
Treatment characteristics
Treatment duration
6/8 weeks h 0 0% 0 0% 0 0% 0 0%
12 weeks 17 100% 40 100% 3 100% 15 56%
16 or 20 weeks 0 0% 0 0% 0 0% 0 0%
24 weeks 0 0% 0 0% 0 0% 12 44%
48 weeks 0 0% 0 0% 0 0% 0 0%
Missing 0 0% 0 0% 0 0% 0 0%
DAA era i
Early 0 0% 0 0% 0 0% 15 56%
Mid 17 100% 40 100% 3 100% 12 44%
Recent 0 0% 0 0% 0 0% 0 0%

Abbreviations: DAA, direct‐acting antiviral; FIB4, fibrosis 4; HBsAg, hepatitis B virus surface antigen; HIV, human immunodeficiency virus; SD, standard deviation; SVR, sustained virologic response; VL, viral load.

a

Registries from country‐wide national HCV ministries of health.

b

Large health care systems.

c

Non‐governmental organizations with programmatic data including across multiple countries.

d

Specific funded research projects.

e

Clinical trial registries from two large pharmaceutical companies (Gilead and AbbVie).

g

Genotype is imputed for Egypt based on previously identified distributions; the majority are genotype 4, and genotyping is no longer undertaken routinely.

h

4 individuals had 6 weeks of treatment in a clinical trial.

i

Early era DAAs (sofosbuvir/ribavirin and sofosbuvir/simeprevir with or without ribavirin), mid‐era (sof/daclatasvir, sof/ledipasvir and elbasvir/grazoprevir‐, or ombitasvir/paritaprevir‐containing regimens) and recent era (glecaprevir/pibrentasvir and sof/velpatasvir regimens).

f

Three individuals had a recorded VL > 1,000,000,000 and were not included in the mean due to likely data entry error.